相关临床试验
20
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
10.0%
已完成
10
50.0%
尚未招募
2
10.0%
招募中
6
30.0%
暂无批准数据
- Pharmazz's Phase IV interim analysis of sovateltide (Tycamzzi®) in 80 acute ischemic stroke patients showed 92.3% achieved favorable functional outcomes compared to 58.5% in controls. - The endothelin-B receptor agonist demonstrated an absolute 33% increase in favorable outcomes with an odds ratio of 8.50 and no drug-related adverse events. - Over 100,000 patients have been treated with sovateltide since its India launch in September 2023, while a global Phase III trial is underway across multiple countries.
- Sun Pharma has signed an agreement to invest up to $25 million in US-based Pharmazz, increasing its stake to approximately 22.7% on a fully diluted basis. - Pharmazz specializes in developing drugs for stroke and hypovolemic shock that have already received approval in India. - The strategic investment aligns with Sun Pharma's expansion into specialty therapeutics and strengthens its presence in critical care medicine. - Despite the significant investment announcement, Sun Pharma's stock remained flat following the news.
